Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study of Galapagos CAR T-cell therapies
2023-510173-34-00Phase 3Authorised
- Sponsor
- Lakefront Biotherapeutics
- Start
- Sep 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 5
01
Overview
Phase 3, open-label trial of GLPG5301 and GLPG5201 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mature B-cell lymphoma and multiple myeloma (MM) (3 arms), sponsored by Lakefront Biotherapeutics. Primary endpoints: Type and incidence of targeted adverse events, Type and incidence of related serious adverse events and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
GLPG5301GLPG5201
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on 2023-510173-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510173-34-00.